A Swiss study shows that quinolones are increasingly used over trimethoprim/sulfamethoxazole for the treatment of urinary tract infection (February 03, 2012)

A new Italian study shows that levofloxacin prophylaxis is effective prophylaxis for patients undergoing hematopoietic stem cell transplantation(June 17, 2011)

Review of treatments for MDR and XDR tuberculosis recommends high-dose levofloxacin(September 10, 2010)

An American study shows that levofloxacin is more cost-effective than moxifloxacin for outpatient CAP treatment(December 18, 2009)

Asian-Pacific Consensus Guidelines recommend levofloxacin for H. pylori infection(October 16, 2009)

Gatifloxacin (TEQUIN) was withdrawn from sale
The FDA issued a notice to determine that TEQUIN (gatifloxacin) Tablets, Injection, and Oral Suspension, were withdrawn from sale for reasons of safety or effectiveness.(October 17, 2008)

Moxifloxacin (AVELOX) and Serious Side Effects
Bayer has sent out letters warning European doctors about a number of reports of serious liver and skin side effects found in patients taking its fluoroquinolone antibiotic, AVELOX(March 17, 2008)

US doctors report a case of Torsade de Pointes associated with moxifloxacin use(March 07, 2007)

FDA Panel Urges Limits on Telithromycin (KETEK)
The FDA advisory panel has concluded that telithromycin (KETEK) should not be sold to patients with sinusitis or bronchitis. It could still be used for mild to moderate pneumonia.(December 18, 2006)